posted Feb 25, 2010 8:13 AM by EBF European Bioanalysis Forum
The Dried Blood Spot (DBS) technique is getting a lot of attention and its advantages are now recognized in the bioanalytical, clinical and non clinical community. In preclinical drug development, DBS offers ethical benefits with regards to the ‘3Rs’ guiding principles: the reduced blood volume needed for DBS enables serial blood sampling from one animal rather than bleeds from several animals which significantly reduces the number of animals and improves the quality of the data for pharmacokinetic and toxicokinetic preclinical studies. Considering clinical applications, DBS offers the advantage of less invasive sampling like finger prick rather than by venous cannulation and the lower blood volume required is a great advantage in paediatrics too. Finally, DBS offers logistical and cost benefits including ease of sample handling, storage and shipment of the DBS cards at room temperature.
The Workshop is organised as an open discussion forum to meet the requirements and expectations of professionals from the generic and the research based industry, CROs, instrument vendors, academia and regulatory agencies. Department heads, project managers, bioanalytical scientists and consultants in R&D, in regulatory affairs, quality assurance, pharmacokinetics and clinical studies and so forth should attend in order to contribute with their experience. All delegates are invited to contribute actively to the scientific discussions across the disciplines. |
Ċ ď EBF European Bioanalysis Forum, Feb 25, 2010 8:14 AM
|
